Kiltearn Partners’s Bristol-Myers Squibb BMY Stock Holding History

Kiltearn Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-349,500	Closed	-$24.8M	–	32
2022 Q3	$24.8M	Sell	349,500 -58,700	-14%	-$4.26M	1.44%	29
2022 Q2	$31.4M	Sell	408,200 -146,300	-26%	-$11.1M	1.65%	30
2022 Q1	$40.5M	Sell	554,500 -1,900	-0.3%	-$128K	1.74%	28
2021 Q4	$34.7M	Sell	556,400 -20,000	-3%	-$1.17M	1.43%	29
2021 Q3	$34.1M	Sell	576,400 -11,100	-2%	-$731K	1.41%	29
2021 Q2	$39.3M	Buy	+587,500	New	+$38.3M	1.57%	26

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Kiltearn Partners's BMY Position: Q4 2022 in Review

Kiltearn Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2022, closing a stake of 349,500 shares — an estimated $24.8M sold.

Kiltearn Partners first reported a position in BMY in Q2 2021 and held it in 6 quarters. The position peaked at $40.5M in Q1 2022. 2,600 funds tracked by Wall St. Rank hold BMY as of Q4 2022.

Kiltearn Partners reported no remaining Bristol-Myers Squibb position as of Q4 2022 after selling out during the quarter.
Kiltearn Partners sold 349,500 Bristol-Myers Squibb shares in Q4 2022, an estimated $24.8M.
Kiltearn Partners first reported a position in Bristol-Myers Squibb in Q2 2021 and held it in 6 quarters.
Kiltearn Partners's Bristol-Myers Squibb position peaked at $40.5M in Q1 2022.
2,600 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.

Based on Kiltearn Partners's 13F filing for Q4 2022, filed 9 Feb 2023.